CliffBio
small molecule

TRIUMEQ PD

ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE

Loss of exclusivityJune 2030latest FDA-listed patent expiry
CompanyViiV Healthcare →View the full company profile on CliffBio

Drug detail

Brand nameTRIUMEQ PD
Active ingredientABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE
StrengthEQ 60MG BASE;EQ 5MG BASE;30MG
Dosage formTABLET, FOR SUSPENSION
RouteORAL
ModalitySmall molecule
FDA approvalMarch 2022
Marketing statusRX

Listed patents

PatentExpiresType
9242986*PEDJune 2030—
9242986December 2029substance, product
8129385*PEDApril 2028—
8129385October 2027substance, product

Regulatory exclusivity

CodeExpires
PEDDecember 2026
NPPJune 2026

More from ViiV Healthcare

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

TRIUMEQ PD patent cliff — loss of exclusivity June 2030 | CliffBio